Search Results

DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced that it completed exclusive commercial licensing of a gene editing technology from the University of California Berkeley.

Elegen Launches ENFINIA ™ DNA Enhancement for Rapid Synthesis of Highly Complex DNA.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced the pricing of a public offering with gross proceeds to the Company expected to be approximately $12.0 million, before deducting placement agent fees and other estimated expenses payable by the Company.

DNA Diagnostics Center Partners with Contraline in ADAM TM Clinical Trial, Testing Revolutionary Male Contraceptive.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health (“NYSDOH”) approved the Company’s TR8™ PGx (“TR8") pharmacogenomic (PGx) testing service.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced consolidated financial results for its second fiscal quarter ended March 31, 2024.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on May 9, 2024, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

YolTech has partnered with KACTUS, a leading developer serving the biopharmaceutical industry, to advance the commercialization of YolTech’s proprietary DNA editor, YolCas12TM, in Greater China.

Applied DNA Sciences, Inc. announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC, will utilize the GenXys Health Care Systems suite of clinical decision support software for interpretation and reporting of ADCL’s New York State Department of Health-approved TR8™ pharmacogenomic test.